Nuvalent (NUVL) Interest Expenses (2020 - 2026)
Nuvalent's (NUVL) quarterly Interest Expenses came in at $465.5 million in Q1 2026, up 39.27% YoY from $334.3 million in Q1 2025, and down 2.28% on a QoQ basis from $476.4 million in Q4 2025.
Nuvalent (NUVL) Interest Expenses (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Interest Expenses data on file, last reported at $465.5 million in Q1 2026.
- Quarterly Interest Expenses rose 39.27% year-over-year to $465.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $465.5 million (up 39.27% YoY) and the FY2025 annual result came in at $476.4 million, up 19.56% from the prior year.
- Interest Expenses retreated to $465.5 million in Q1 2026, from $476.4 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $617.6 million in Q3 2024 to a low of $512000.0 in Q1 2023.
- A 5-year average of $233.6 million and a median of $334.3 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses tumbled 94.25% — and 2024, when it surged 47044.12%.
- Tracing NUVL's Interest Expenses over 5 years: stood at $1.3 million in 2022, then surged by 33312.86% to $449.4 million in 2023, then retreated by 11.35% to $398.4 million in 2024, then gained by 19.56% to $476.4 million in 2025, then dropped by 2.28% to $465.5 million in 2026.
- The last three Interest Expenses figures came in at $465.5 million (Q1 2026), $476.4 million (Q4 2025), and $428.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 465.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 465.51 Mn |
| Mar 31, 2026 | 465.51 Mn |
| Dec 31, 2025 | 476.36 Mn |
| Dec 31, 2025 | 476.36 Mn |
| Sep 30, 2025 | 428.90 Mn |
| Sep 30, 2025 | 428.90 Mn |
| Jun 30, 2025 | 360.93 Mn |
| Jun 30, 2025 | 360.93 Mn |
| Mar 31, 2025 | 334.26 Mn |
| Mar 31, 2025 | 334.26 Mn |
| Dec 31, 2024 | 398.41 Mn |
| Dec 31, 2024 | 398.41 Mn |
| Sep 30, 2024 | 617.59 Mn |
| Sep 30, 2024 | 617.59 Mn |
| Jun 30, 2024 | 430.98 Mn |
| Jun 30, 2024 | 430.98 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Mar 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | 449.40 Mn |
| Dec 31, 2023 | 449.40 Mn |